Memory T Cells Are Uniquely Resistant to Melanoma-induced Suppression
Overview
Oncology
Pharmacology
Affiliations
We have previously observed that in vivo exposure to growing melanoma tumors fundamentally alters activated T cell homeostasis by suppressing the ability of naïve T cells to undergo antigen-driven proliferative expansion. We hypothesized that exposure of T cells in later stages of differentiation to melanoma would have similar suppressive consequences. C57BL/6 mice were inoculated with media or syngeneic B16F10 melanoma tumors 8 or 60 days after infection with lymphocytic choriomeningitis virus (LCMV), and splenic populations of LCMV-specific T cells were quantified using flow cytometry 18 days after tumor inoculation. Inoculation with melanoma on post-infection day 8 potentiated the contraction of previously activated T cells. This enhanced contraction was associated with increased apoptotic susceptibility among T cells from tumor-bearing mice. In contrast, inoculation with melanoma on post-infection day 60 did not affect the ability of previously established memory T cells to maintain themselves in stable numbers. In addition, the ability of previously established memory T cells to respond to LCMV challenge was unaffected by melanoma. Following adoptive transfer into melanoma-bearing mice, tumor-specific memory T cells were significantly more effective at controlling melanoma growth than equivalent numbers of tumor-specific effector T cells. These observations suggest that memory T cells are uniquely resistant to suppressive influences exerted by melanoma on activated T cell homeostasis; these findings may have implications for T cell-based cancer immunotherapy.
Kansy B, Wehrs T, Bruderek K, Si Y, Ludwig S, Droege F Cancer Immunol Immunother. 2023; 72(12):4367-4383.
PMID: 38019346 PMC: 10700222. DOI: 10.1007/s00262-023-03571-8.
Pepple A, Guy J, McGinnis R, Felsted A, Song B, Hubbard R Front Immunol. 2023; 14:1012799.
PMID: 36756111 PMC: 9900174. DOI: 10.3389/fimmu.2023.1012799.
The ER-Mitochondria Interface as a Dynamic Hub for T Cell Efficacy in Solid Tumors.
Hunt E, Andrews A, Larsen S, Thaxton J Front Cell Dev Biol. 2022; 10:867341.
PMID: 35573704 PMC: 9091306. DOI: 10.3389/fcell.2022.867341.
Qu S, Worlikar T, Felsted A, Ganguly A, Beems M, Hubbard R J Immunother Cancer. 2020; 8(1).
PMID: 31940590 PMC: 7057529. DOI: 10.1136/jitc-2019-000200.
Contreras A, Beems M, Tatar A, Sen S, Srinand P, Suresh M J Immunother Cancer. 2018; 6(1):41.
PMID: 29843822 PMC: 5975512. DOI: 10.1186/s40425-018-0358-2.